Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy

Mariano Arribas, Gregory J Ahmann, BS, Skye Buckner-Petty, MPH, Esteban Braggio, PhD, Elitza S Theel, PhD, Rafael Fonseca, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-142616

Published: 2020

Journal Articles

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Miguel Gonzalez-Velez, MD, Mariano Arribas, Heidi E. Kosiorek, MS, Richard Butterfield, III, Carlo Guerrero, MD, Luke Mountjoy, DO, Jeremy Larsen, Craig B. Reeder, MD, P. Leif Bergsagel, MD, A. Keith Stewart, MB, ChB, Rafael Fonseca, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142845

Published: 2020

Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136985

Published: 2020

Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1904.

https://doi.org/10.1182/blood-2019-131478

Published: 2019

Journal Articles

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Sinto Chirackal, PhD, Esteban Braggio, PhD, Rahman Atiqur, PhD, Gregory J Ahmann, BS, Yuan Xiao Zhu, PhD, A. Keith Stewart, MB, ChB, Marta Chesi, PhD, P. Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2019) 134 (Supplement_1): 4410.

https://doi.org/10.1182/blood-2019-124967

Published: 2019

Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA

Blood (2019) 134 (Supplement_1): 2211.

https://doi.org/10.1182/blood-2019-123743

Published: 2019

Journal Articles

Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMIDs) Sensitivity in Myeloma

Luke Mountjoy, DO, Sinto Chirackal, PhD, Tania Jain, MD, Marlene Girardo, MS, Jeremy Larsen, MD, Rafael Fonseca, MD

Blood (2018) 132 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2018-99-113710

Published: 2018

Journal Articles

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

Rafael Fonseca, MD, Saad Z. Usmani, MD, Maneesha Mehra, Mary Slavcev, Jon Ukropec, PhD, Annette Lam, Ravi Potluri

Blood (2018) 132 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2018-99-113125

Published: 2018

Journal Articles

Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

May Hagiwara, PhD, Thomas Delea, MBA, MSIA, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Rafael Fonseca, MD

Blood (2018) 132 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2018-99-117230

Published: 2018

Journal Articles

Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT)

Rafael Fonseca, MD, Kejal Parikh, BSPharm, MS, Brian Ung, PharmD, Quanhong Ni, MS, Safiya Abouzaid, MPH, PharmD, Amit Agarwal, MD PhD

Blood (2017) 130 (Supplement 1): 3463.

https://doi.org/10.1182/blood.V130.Suppl_1.3463.3463

Published: 2017

Journal Articles

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Sikander Ailawadhi, Abdel-Ghani Azzouqa, Zahara Meghji, Tania Jain, MD, Nancy Diehl, Stephanie P. Gebhardt, Vishal Shah, David O. Hodge, MS, Raj Patel, MD, Prachi Jani, MD, Taimur Sher, MD, Vivek Roy, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Rafael Fonseca, MD

Blood (2017) 130 (Supplement 1): 5440.

https://doi.org/10.1182/blood.V130.Suppl_1.5440.5440

Published: 2017

Journal Articles

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Sumita Bhatta, MD, Lori Cyprien, Rafael Fonseca, MD, Rohini K Hernandez, PhD, Christopher Kim, PhD

Blood (2017) 130 (Supplement 1): 2171.

https://doi.org/10.1182/blood.V130.Suppl_1.2171.2171

Published: 2017

Journal Articles

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

Tania Jain, MD, Rafael Fonseca, MD, Ruqin Chen, MD, Raj Patel, MD, Prachi Jani, MD, Veronica Gonzalez De La Calle, MD, Zahara Meghji, James E. Hoffman, MD, Alvaro J. Alencar, MD, Kevin R Kelly, MD PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2017) 130 (Supplement 1): 864.

https://doi.org/10.1182/blood.V130.Suppl_1.864.864

Published: 2017

Journal Articles

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Niamh Keane, MB, MRCP, Caleb K Stein, MS, Daniel Angelov, MSc,MB, Shulan Tian, David Viswanatha, MD, Shaji K Kumar, MD, Angela Dispenzieri, MD, Veronica Gonzalez De La Calle, MD, Kristine Misund, PhD, Robert A Kyle, MD, Michael E O'Dwyer, MD, Rafael Fonseca, MD, A. Keith Stewart, MBChB, MBA, Esteban Braggio, PhD, Yan Asmann, PhD, S. Vincent Rajkumar, MD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 393.

https://doi.org/10.1182/blood.V130.Suppl_1.393.393

Published: 2017

Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD

Blood (2017) 130 (Supplement 1): 4288.

https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288

Published: 2017

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53 in Chromosome 17p13

Phaik Ju Teoh, PhD, Tae-Hoon Chung, Chirackal Sintosebastian, Rafael Fonseca, MD, Wee Joo Chng, MB ChB, MRCP, PhD

Blood (2017) 130 (Supplement 1): 1761.

https://doi.org/10.1182/blood.V130.Suppl_1.1761.1761

Published: 2017

Journal Articles

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria X Wang, Santiago Garcia, PhD, Laura Ann Bruins, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 4373.

https://doi.org/10.1182/blood.V128.22.4373.4373

Published: 2016

Journal Articles

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Tania Jain, M.B.,B.S, Shu Ting Kung, MD, Vishal Shah, Pharm.D., R.Ph., Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, P. Leif Bergsagel, MD, Craig B. Reeder, MD, Pierre Noel, MD, Roberta H. Adams, MD, Susan Luft, M.S., R.N., Angela Mayo, P.A.-C., M.S., A. Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4629.

https://doi.org/10.1182/blood.V128.22.4629.4629

Published: 2016

NARROW

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMIDs) Sensitivity in Myeloma

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT)

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53 in Chromosome 17p13

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only